Atlas Trials

A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer

Clinical trial NCT04506554 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04506554
Sponsor
Fox Chase Cancer Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Muscle-Invasive Bladder Carcinoma
Start date
2020-12-01
Primary completion
2026-05-01
Enrollment
81

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.